Opeyemi S. Adeniji

Opeyemi S. Adeniji

Auto-generated profile, based on publicly available information

Opeyemi S. Adeniji

Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2023 in Science Advances
Verified
Journal Article
Open access
DBDevivasha Bordoloi
Devivasha Bordoloi
AKAbhijeet J. Kulkarni
Abhijeet J. Kulkarni
OAOpeyemi S. Adeniji
Opeyemi S. Adeniji
MPM. Betina Pampena
M. Betina Pampena
PBPratik S. Bhojnagarwala
Pratik S. Bhojnagarwala
DWDavid Weiner
David Weiner
Ovarian cancer (OC) is a lethal gynecologic malignancy, with modest responses to CPI. Engagement of additional immune arms, such as NK cells, may be of value. We focused on Siglec-7 as a surface antigen for engaging this population. Human antibodies against Siglec-7 were developed and characterized. Coculture of OC cells with PBMCs/NKs and Siglec-7 binding antibodies showed NK-mediated killing of OC lines. Anti–Siglec-7 mAb (DB7.2) enhanced survival in OC-challenged mice. In addition, the combination of DB7.2 and anti–PD-1 demonstrated further improved OC killing in vitro. To use Siglec-7 engagement as an OC-specific strategy, we engineered an NK cell engager (NKCE) to simultaneously engage NK cells through Siglec-7, and OC targets through FSHR. The NKCE demonstrated robust in vitro killing of FSHR + OC, controlled tumors, and improved survival in OC-challenged mice. These studies support additional investigation of the Siglec-7 targeting approaches as important tools for OC and other recalcitrant cancers.